Trial Profile
A Multi-center, Randomized, Double-blind, Active-controlled, Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Metformin/Atorvastatin Combination Therapy in Subjects With Type II Diabetes and Dyslipidemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jun 2023
Price :
$35
*
At a glance
- Drugs Atorvastatin/metformin (Primary) ; Atorvastatin; Metformin
- Indications Dyslipidaemias; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Daewoong Pharmaceutical
- 15 Jun 2023 Status changed from recruiting to completed.
- 15 Nov 2016 New trial record